Skip to content
OpenCapital
Get started

Zymeworks ZYME Lease Liability Payments - 2021

Lease Liability Payments - 2021 at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$1.05M-29.4%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's lease liability payments - 2021.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's lease liability payments - 2021?
Zymeworks (ZYME) reported lease liability payments - 2021 of $4.2M in Q1 2026.
How has Zymeworks's lease liability payments - 2021 changed year-over-year?
Zymeworks's lease liability payments - 2021 increased by 4.0% year-over-year, from $4.04M to $4.2M.
What does lease liability payments - 2021 mean?
This metric captures the total contractual cash payments due for operating and finance leases specifically during the 2021 fiscal period. It serves as a historical or forward-looking benchmark for lease-related cash outflows. It is used by analysts to model the company's fixed cost structure and cash flow requirements.